EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alkermes's enterprise value is $4,413 Mil.
Alkermes's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $467 Mil. Therefore, Alkermes's EV-to-EBITDA for today is 9.45.
The historical rank and industry rank for Alkermes's EV-to-EBITDA or its related term are showing as below:
ALKS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1324.08 Med: 6.68 Max: 27344.95
Current: 9.45
During the past 13 years, the highest EV-to-EBITDA of Alkermes was 27344.95. The lowest was -1324.08. And the median was 6.68.
ALKS's EV-to-EBITDA is ranked better than 64.31% of 737
companies
in the Drug Manufacturers industry
Industry Median: 13.41
vs ALKS: 9.45
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Alkermes EV-to-EBITDA Historical Data
The historical data trend for Alkermes's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkermes's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkermes's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alkermes's EV-to-EBITDA falls into.
Alkermes's current Enterprise Value is $4,413 Mil.
Alkermes's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $467 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkermes (NAS:ALKS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alkermes's share price for today is $30.53.
Alkermes's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.090.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Alkermes's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALKS has been successfully added to your 